Fiona Hartley

My research focuses on the role of insulin-like growth factors (IGFs) in prostate cancer. IGFs binds to cell surface receptors and promote cancer cell growth and therapy resistance. Men with high levels of circulating IGF are at greater risk of developing prostate cancer. The WINGMEN clinical trial treated men diagnosed with early prostate cancer with the IGF inhibitory antibody xentuzumab. My role is to analyse data from this clinical trial to investigate how xentuzumab treatment affects the tumours and to identify biomarkers for patients who would benefit from IGF inhibition.

I graduated from the University of Leeds in 2016 with a B.Sc. in Biological Sciences (Industrial). During my undergraduate, I spent a year working in pre-clinical toxicology at GlaxoSmithKline.  I completed my M.Sc. by Research at the University of Oxford in 2018 and my DPhil in Oncology in 2024.